<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="reply"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Indian J Ophthalmol</journal-id><journal-id journal-id-type="publisher-id">Indian Journal of Ophthalmology</journal-id><journal-title-group><journal-title>Indian Journal of Ophthalmology</journal-title></journal-title-group><issn pub-type="ppub">0301-4738</issn><issn pub-type="epub">1998-3689</issn><publisher><publisher-name>Medknow Publications</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">2636111</article-id><article-id pub-id-type="publisher-id">IndianJOphthalmol_2008_56_3_256_40376</article-id><article-categories><subj-group subj-group-type="heading"><subject>Letter to the Editor</subject></subj-group></article-categories><title-group><article-title>Author&#x02032;s reply</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Nagpal</surname><given-names>Manish</given-names></name><degrees>FRCS</degrees></contrib><contrib contrib-type="author"><name><surname>Nagpal</surname><given-names>Kamal</given-names></name><degrees>MS</degrees></contrib><contrib contrib-type="author"><name><surname>Nagpal</surname><given-names>PN</given-names></name><degrees>MS, FACS</degrees></contrib></contrib-group><aff>Retina Foundation, Ahmedabad, Gujarat, India</aff><author-notes><corresp id="cor1">Correspondence to Dr. Manish Nagpal, Retina Foundation,Shahibag, Ahmedabad - 380 014, Gujarat, India. Email: <email>drmanishnagpal@yahoo.com</email></corresp></author-notes><pub-date pub-type="ppub"><season>May-Jun</season><year>2008</year></pub-date><volume>56</volume><issue>3</issue><fpage seq="a">256</fpage><lpage>256</lpage><permissions><copyright-statement>Copyright: &#x000a9; Indian Journal of Ophthalmology</copyright-statement><copyright-year>2008</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><related-article related-article-type="letter" vol="56" page="255" ext-link-type="pmc" id="RA1"><article-title>Debate on the various anti-vascular endothelial growth factor drugs</article-title></related-article></article-meta></front><body><p>Dear Editor,</p><p>We thank Khalili <italic>et al</italic>. for their valuable comments<xref ref-type="bibr" rid="ref1">1</xref> inresponse to our article, &#x02033;A comparative debate on the variousanti-vascular endothelial growth factor drugs: Pegaptanibsodium (Macugen), ranibizumab (Lucentis) and bevacizumab(Avastin)&#x02033;.<xref ref-type="bibr" rid="ref2">2</xref></p><p>The recent study by Nishijama <italic>et al</italic>.,<xref ref-type="bibr" rid="ref3">3</xref> recognized vascularendothelial growth factor (VEGF)-A as an importantneuroprotectant in neural cell survival, in a model of ischemia-reperfusion injury. Ischemic preconditioning 24 h beforeischemia-reperfusion injury increased VEGF-A levels andsubstantially decreased the number of apoptotic retinal cells.The protective effect of ischemic preconditioning was reversedafter VEGF-A inhibition. Chronic inhibition of VEGF-A innormal adult animals resulted in loss of retinal ganglia.Therefore, it appears to be critical for retinal neuron survival,especially in response to ischemia in animal models. The clinicalinterpretation of this information would definitely point towardthe importance of selective anti-VEGF agents in the context ofischemic retinal diseases.</p><p>Vascular endothelial growth factor-A, produced by a singlegene on chromosome 6p21.3, consists of eight exons and sevenintrons, which produce as many as six different isoformsthrough alternative splicing, 121, 145, 165, 183, 189 and 206amino acids in length. These different isoforms vary in theiraffinity for heparin binding and therefore in their affinity forthe extracellular matrix. The larger isoforms, such as VEGF-189 and VEGF-206, bind heparin with high affinity and aretherefore, almost completely sequestered in the extracellularmatrix. The smaller isoform, VEGF-121, does not bind heparinand is freely diffusible.<xref ref-type="bibr" rid="ref4">4</xref></p><p>Another study<xref ref-type="bibr" rid="ref5">5</xref> characterized VEGF localization in diabeticretinopathy using staining pattern of VEGF at different stagesof diabetic retinopathy. They found that staining with theVEGF<sub>165</sub> antibody was generally confined to endothelial cells andperivascular regions, while the VEGF<sub>121,165,189</sub> antibody was alsoassociated with extravascular components of the inner retina.</p><p>It is likely that there is a spatial preference of different VEGFisoforms. It appears that ischemic retinopathies are likely tobe more responsive to selective VEGF inhibition, while allisoforms of VEGF which may be responsible for proliferationcan be localized to the subretinal space in exudative age-relatedmacular degeneration (AMD). Even from a systemic safetyperspective, selective inhibition is more important for ischemicretinopathies than it is in AMD. However, with the availabilityof selective as well as pan-VEGF blockade agents, the roles,indications and contraindications of each will require large,prospective, planned studies.</p></body><back><ref-list><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohammad R</surname><given-names>Khalili</given-names></name><name><surname>Hamid</surname><given-names>Hosseini</given-names></name></person-group><article-title>Debate on the various anti-vascular endothelial growth factor drugs</article-title><source>Indian J Ophthalmol</source><year>2008</year><volume>56</volume><fpage>249</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">18417834</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagpal</surname><given-names>M</given-names></name><name><surname>Nagpal</surname><given-names>K</given-names></name><name><surname>Nagpal</surname><given-names>PN</given-names></name></person-group><article-title>A comparative debate on thevarious anti-vascular endothelial growth factor drugs: Pegaptanibsodium (Macugen), ranibizumab (Lucentis) and bevacizumab(Avastin)</article-title><source>Indian J Ophthalmol</source><year>2007</year><volume>55</volume><fpage>437</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">17951900</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishijima</surname><given-names>K</given-names></name><name><surname>Ng</surname><given-names>YS</given-names></name><name><surname>Zhong</surname><given-names>L</given-names></name><name><surname>Bradley</surname><given-names>J</given-names></name><name><surname>Schubert</surname><given-names>W</given-names></name><name><surname>Jo</surname><given-names>N</given-names></name><etal/></person-group><article-title>Vascular endothelial growth factor: A is a survival factor forretinal neurons and a critical neuroprotectant during the adaptiveresponse to ischemic injury</article-title><source>Am J Pathol</source><year>2007</year><volume>171</volume><fpage>53</fpage><lpage>67</lpage><pub-id pub-id-type="pmid">17591953</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>C</given-names></name><name><surname>Stinger</surname><given-names>S</given-names></name></person-group><article-title>The splice variants of vascular endothelialgrowth factor (VEGF) and their receptors</article-title><source>J Cell Sci</source><year>2001</year><volume>114</volume><fpage>853</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">11181169</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boulton</surname><given-names>M</given-names></name><name><surname>Foreman</surname><given-names>D</given-names></name><name><surname>Williams</surname><given-names>G</given-names></name><name><surname>McLeod</surname><given-names>D</given-names></name></person-group><article-title>VEGF localisation in diabetic retinopathy</article-title><source>Br J Ophthalmol</source><year>1998</year><volume>82</volume><fpage>561</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">9713066</pub-id></element-citation></ref></ref-list></back></article>